ClinicalTrials.gg
RecruitingNCT07894471Updated Oct 26, 2026

Comparison of Surgery With Prehabilitation, Direct Surgery and Rehabilitation for Patients With Femoroacetabular Impingement

An interventional study of Hip arthroscopic surgery and Standardized physical rehabilitation training in Femoroacetabular Impingement Syndrome, sponsored by Peking University Third Hospital. Recruiting at 1 site in China. Open to participants aged 16 Years and older. Per ClinicalTrials.gov, last updated 2026-10-26.

Sponsored by Peking University Third Hospital · Not applicable, Interventional, and Treatment

From the registry’s dates

  • Registered 3 months after the study started (first participant enrolled Jul 2026, registered Oct 2026).
  • Started Jul 2026; still recruiting 3 months later.
Updated Oct 26, 2026Newly registeredGo to Updates ↓
Phase
Not applicable
Study type
Interventional
Enrollment
360
Allocation
Non-randomized
Ages
16 Years and older
Sex
All
01

Study summary

This study aims to compare the therapeutic effects of three different treatment strategies for patients with femoroacetabular impingement. Participants will be randomly assigned to one of three groups: surgery combined with pre-rehabilitation, direct surgery without pre-rehabilitation, or rehabilitation alone. Researchers will follow-up participants and evaluate pain, joint function and other outcomes to find out which treatment works better.

Read the detailed description
  1. Background and Rationale Femoroacetabular impingement (FAI) is a common sports-related disorder of the hip caused by abnormal anatomical morphology of the proximal femur and the acetabulum. Diagnosis requires the combination of patient-reported symptoms, physical examination findings, and imaging abnormalities. Affected patients typically present with activity-related groin or peritrochanteric pain, mechanical symptoms such as clicking, and reduced range of motion. If left untreated, repetitive abnormal osseous impingement can damage the acetabular labrum and articular cartilage, accelerating the degenerative progression toward hip osteoarthritis.

    Current management strategies for FAI center on conservative rehabilitation (primarily physiotherapy) and minimally invasive hip arthroscopic surgery. However, the optimal treatment pathway among rehabilitation alone, direct surgery, and the combination of surgery with preoperative rehabilitation remains controversial, and high-level comparative evidence is lacking.

    Physical rehabilitation and hip arthroscopy have distinct and complementary mechanisms of action, yet their relative efficacy and appropriate indications are not fully defined. Rehabilitation focuses on correcting abnormal movement patterns and strengthening pelvic and core stability; it is non-invasive and associated with fewer complications, but it cannot eliminate the underlying Cam- or Pincer-type osseous deformity. Consequently, patients with significant structural impingement often experience recurrent pain and difficulty returning to high-level sport after conservative treatment alone. In contrast, hip arthroscopy allows precise resection of the impinging osseous deformity and repair or reconstruction of the damaged labrum, and it has become the mainstream treatment for patients with moderate-to-severe disease. Nevertheless, functional recovery and long-term satisfaction after direct surgery vary considerably among individuals; a substantial proportion of patients experience delayed functional recovery and slow pain relief in the early postoperative period due to pre-existing muscle atrophy, impaired neuromuscular proprioception, and the physiological stress of surgical trauma.

    Introducing prehabilitation into the perioperative management of FAI offers a promising approach to address this limitation. Preoperative exercise-based prehabilitation aims to improve patients' physiological reserve and neuromuscular compensation through targeted functional exercise, strength conditioning, and patient education before surgery, thereby improving tolerance of the surgical insult and accelerating postoperative recovery. Although a few randomized trials have suggested that a short preoperative prehabilitation program may improve certain early postoperative functional outcomes, current evidence remains insufficient to demonstrate sustained medium- and long-term gains in clinically meaningful patient-reported outcomes. More importantly, no prospective three-arm trial has directly compared surgery combined with prehabilitation, direct surgery, and standardized rehabilitation alone within a single evaluation framework, leaving clinicians without high-level evidence to guide stepped care decision-making.

  2. Objectives This study systematically compares the clinical efficacy of three treatment strategies - surgery combined with prehabilitation, direct hip arthroscopic surgery, and standardized rehabilitation alone - in patients with FAI. The primary focus is on patient-reported outcomes, including the iHOT-12 and HOS instruments, supplemented by dynamic pain scores, hip range of motion, periarticular muscle strength, and return-to-sport (RTS) indicators across the intervention and follow-up periods. The study further explores dynamic changes in periarticular muscle strength and neuromuscular control, aiming to clarify the physiological gains attributable to prehabilitation and their association with long-term postoperative outcomes. The ultimate goal is to define the differential clinical value of each intervention and to provide high-quality evidence for individualized hip-preserving treatment and accelerated perioperative rehabilitation strategies.
  3. Study Design

    This is a prospective, randomized, three-arm, parallel-group controlled trial. Eligible participants are allocated in a 1:1:1 ratio to one of three arms:

    • Arm A (Surgery + Prehabilitation): A structured preoperative prehabilitation program followed by hip arthroscopic surgery.
    • Arm B (Direct Surgery): Conventional hip arthroscopic surgery without preoperative prehabilitation.
    • Arm C (Rehabilitation Alone): A standardized, predominantly home-based progressive rehabilitation program.
  4. Participants

    Inclusion Criteria:

    Presence of hip pain with imaging evidence of Cam- or Pincer-type femoroacetabular impingement morphology; Age ≥ 16 years; Able to provide written informed consent; Physician judgment that the patient is likely to benefit from hip arthroscopic surgery or a rehabilitation program.

    Exclusion Criteria:

    Concomitant hip osteoarthritis (Tönnis grade > 1, or joint space \< 2 mm on the anteroposterior pelvic radiograph); History of prior hip pathology, including Legg-Calvé-Perthes disease, slipped capital femoral epiphysis, or avascular necrosis of the femoral head; History of prior hip trauma, including acetabular fracture, hip dislocation, or femoral neck fracture; Previous hip surgery (open or arthroscopic); Completion of a rehabilitation program specifically for FAIS within the past 12 months; Hip dysplasia (lateral center-edge angle \< 20°).

    Note on bilateral disease: Patients with bilateral FAIS may be enrolled; only the more symptomatic hip is randomized and followed for the purposes of this study.

  5. Interventions Rehabilitation Protocol (Arms A and C): The rehabilitation program is predominantly home-based and progressive, built upon disease education and activity modification. It is designed with reference to prior studies and systematic reviews, and comprises: (1) resistance training of the periarticular hip musculature; (2) functional motor-control training; (3) hip range-of-motion and flexibility training; and (4) trunk and pelvic stability training. The program is performed four times per week, with each session lasting approximately 30-45 minutes. After the baseline assessment, a rehabilitation therapist instructs participants in the exercises and provides training materials. During the intervention, training load, repetitions, range of motion, and exercise difficulty are individually adjusted according to each participant's symptoms, movement quality, and completion status. If symptoms markedly worsen after a session and do not resolve within 24 hours, the load is reduced and the relevant exercises are suspended; if necessary, the participant is evaluated by the rehabilitation therapist or a clinician. Training completion is recorded by the research staff.

    Surgical Intervention (Arms A and B): Hip arthroscopic surgery is performed to resect the impinging osseous deformity and to repair or reconstruct the damaged labrum as appropriate. Detailed intraoperative findings, including labral damage, cartilage injury, round ligament and other intra-articular pathology, as well as the specific surgical procedures performed (labral repair/reconstruction, cartilage treatment, tendon repair, capsular management, osteotomy type and fixation where applicable), are documented.

  6. Outcome Measures

    Primary outcome measures:

    • International Hip Outcome Tool (iHOT-12) score at 6 and 12 months after intervention.

    Secondary outcome measures:

    • Visual Analogue Scale (VAS) pain score;
    • Hip range of motion (active and passive);
    • Periarticular hip muscle strength (manual muscle testing);
    • UCLA Activity-Level Rating Scale;
    • Modified Harris Hip Score (mHHS);
    • Hip Outcome Score (HOS-ADL and HOS-SSS);
    • Psychosocial measures: SF-12 Health Survey, Pittsburgh Sleep Quality Index (PSQI), Pain Catastrophizing Scale (PCS), Patient Health Questionnaire (PHQ), Generalized Anxiety Disorder Scale (GAD), EuroQol 5-Dimension Questionnaire (EQ5D);
    • Imaging assessments (X-ray, CT, MRI) of structural change and recovery.
  7. Assessments and Follow-up Baseline data collection includes demographic characteristics, disease-related data, and preoperative imaging. Outcome assessments are performed at baseline and at 6 and 12 months after the intervention. Subjective functional questionnaires are completed by participants at each follow-up point. Rehabilitation-specific functional assessments (range of motion, manual muscle testing, single-leg stance with eyes closed) are performed by trained rehabilitation professionals. Imaging studies are collected preoperatively and during postoperative follow-up to evaluate structural changes and recovery. Surgical data, including operative approach, intra-articular pathology, and management of the labrum, cartilage, soft tissues, capsule, and osteotomy, are recorded to support analysis of surgical factors on long-term outcomes.
  8. Safety and Adverse Events All examination and rehabilitation activities are performed within the normal range of motion and only to a tolerable extent. Participants are instructed to contact the medical team regarding any discomfort occurring during the study, whether or not it is related to the intervention. Adverse events (AEs) are defined as any untoward medical occurrence after treatment, without necessarily implying a causal relationship. AEs are classified into five categories of causality (definitely related, probably related, possibly related, possibly unrelated, definitely unrelated); the first three categories are counted in the incidence of adverse reactions. Serious adverse events (SAEs) include events requiring hospitalization, prolongation of hospitalization, disability, impairment of working capacity, permanent organ damage, life-threatening events, death, carcinogenicity, teratogenicity, or birth defects. Any SAE or significant adverse event, whether or not related to the intervention, must be reported to the sponsor by telephone or fax within 24 hours of its occurrence or of the investigator becoming aware of it.
  9. Data Management and Statistical Analysis Data are collected via structured questionnaires and entered into a dedicated database using double-entry by two independent operators, followed by two rounds of cross-checking. Queries are exchanged using query forms, which are retained for audit. After verification, the database is locked following review by the principal investigator, sponsor representatives, monitors, data manager, and statistician. Original records are archived according to applicable retention requirements, with multiple electronic backups stored on separate media.

    Statistical analysis is performed using SPSS 26.0 software. Categorical data are expressed as percentages and compared between groups using the chi-square test. Continuous data are expressed as mean ± standard deviation and compared using t-tests or non-parametric tests as appropriate. Spearman correlation analysis and multiple linear regression are used to evaluate associations between psychosocial factors and surgical outcomes. Unless otherwise specified, a two-sided p-value \< 0.05 is considered statistically significant.

  10. Human Subjects Protection and Ethics The trial will not begin until the protocol and informed consent form have been submitted to and approved by the responsible ethics committee. Any protocol amendment will be implemented only after the relevant revised sections and the revised informed consent form (if applicable) have been reviewed and approved by the ethics committee; a copy of the approval letter will be provided to the clinical monitor. Amendments intended to reduce clear risk to participants may be implemented immediately but must be filed with the ethics committee as soon as possible. In accordance with applicable regulations, investigators will provide written and oral explanations of the study background, nature, purpose, procedures, benefits, risks, compensation, injury compensation, and withdrawal rights before enrollment, and written informed consent must be obtained from every participant (or their legal representative). The informed consent form is dated, and both the investigator and the participant retain a copy. Measures to protect confidentiality include: limiting access to participant data to designated personnel; de-identifying data in case report forms (using participant codes rather than names, telephone numbers, or home addresses) with a separate linkage table; and protecting personal privacy in any publication.
  11. Quality Control and Study Management Clinical monitors designated by the sponsor conduct periodic on-site supervision visits to ensure strict adherence to the protocol and accuracy of recorded data. Participating research staff receive uniform training to ensure consistent recording methods and evaluation standards. Monitoring activities include verification of protocol submission and ethics approval, compliance with standard operating procedures, review of the correctness and completeness of case report form data, and verification of all observed findings against source data.
  12. Study Duration and Termination The study is expected to be completed within three years. The trial may be terminated early if: (1) a serious safety issue is identified; (2) the treatment effect is judged too poor to have clinical value; (3) a major protocol error or serious deviation makes the effect unassessable; or (4) the applicant or a regulatory authority requires termination.
02

Conditions studied

  • Femoroacetabular Impingement Syndrome

Keywords

  • Femoroacetabular impingement
  • Hip
  • Hip arthroscopy
  • Rehabilitation
03

In context

Femoracetabular Impingement

110 studies on the registry are indexed under Femoracetabular Impingement; 36 are open to participants now.

This study's planned enrollment of 360 is above the median of 75 across 63 interventional studies indexed under Femoracetabular Impingement.

Browse Femoracetabular Impingement studies →

Lead sponsor

Peking University Third Hospital is the lead sponsor of 749 studies on the registry; 270 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
16 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Presence of hip pain with imaging evidence of Cam- or Pincer-type femoroacetabular impingement morphology;
  2. Age ≥ 16 years;
  3. Able to provide written informed consent;
  4. Physician judgment that the patient is likely to benefit from hip arthroscopic surgery or a rehabilitation program.

Exclusion criteria

Exclusion Criteria:

  1. Concomitant hip osteoarthritis (Tönnis grade > 1, or joint space \< 2 mm on the anteroposterior pelvic radiograph);
  2. History of prior hip pathology, including Legg-Calvé-Perthes disease, slipped capital femoral epiphysis, or avascular necrosis of the femoral head;
  3. History of prior hip trauma, including acetabular fracture, hip dislocation, or femoral neck fracture;
  4. Previous hip surgery (open or arthroscopic);
  5. Completion of a rehabilitation program specifically for FAIS within the past 12 months;
  6. Hip dysplasia (lateral center-edge angle \< 20°).
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
360 participants (estimated)

Study arms

  • Experimental
    Prehabilitation plus hip arthroscopy

    A structured preoperative prehabilitation program followed by hip arthroscopic surgery

    Procedure: Hip arthroscopic surgery · Behavioral: Standardized physical rehabilitation training

  • Active comparator
    Hip arthroscopy alone

    Conventional hip arthroscopic surgery without preoperative prehabilitation

    Procedure: Hip arthroscopic surgery

  • Active comparator
    Conservative rehabilitation alone

    A standardized rehabilitation program

    Behavioral: Standardized physical rehabilitation training

Interventions

  • ProcedureHip arthroscopic surgery

    Hip arthroscopic surgery

  • BehavioralStandardized physical rehabilitation training

    Standardized physical rehabilitation training

06

What researchers measure

Primary outcomes

  1. iHOT-12

    International Hip Outcome Tool (iHOT-12) score

    Time frame: 6 and 12 months

Secondary outcomes

  1. mHHS

    Modified Harris Hip Score

    Time frame: 6 and 12 months

07

Study locations

1 of 1 sites recruiting
  • Peking University Third Hospital
    Beijing, 100191, China
    Recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jul 2026 (actual). Primary completion is estimated for Jul 2036, 120 months after the start.

Of 37 non-industry interventional studies with no phase under Femoracetabular Impingement, half reached primary completion within 41 months of starting (the median), counting those still running; a quarter within 30 and three quarters within 79. This study's planned 120 months is above that.

Counting every sponsor, half of 38 studies reached it within 41 months; a quarter within 30 and three quarters within 79.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 19, 2026
First posted
Oct 26, 2026
StartActual
Jul 6, 2026
Primary completionEst.
Jul 2036
CompletionEst.
Jul 2036
Last update
Oct 26, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Oct 26, 2026
Show all 1 update
  1. Oct 26, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07894471
Responsible party
Sponsor
First posted
Oct 26, 2026
Start date
Jul 6, 2026
Primary completion
Jul 2036 (estimated)
Completion
Jul 2036 (estimated)
Last update
Oct 26, 2026

Study contacts

Yan Xu, MD, PhD
Contact
yanxu@139.com
+8613701130401
Cancan Du, PhD
Contact
ducancan@bjmu.edu.cn
+8613552589034

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion